News
Viva in Vitro in the media
News
Sensible Management of Retribution to Capital in Biotech Startups
In the dynamic realm of biotech startups, the judicious management of capital and the strategic application of retribution to capital techniques are pivotal for fostering growth and securing long-term sustainability.
DeepTech or The Art of Balancing Capital and Innovation: Strategic Considerations for Biotech CEOs on Cost of Equity
In the high-stakes arena of biotechnological and medical devices startups, the CEO’s role transcends the realms of innovation and enters the intricate world of financial strategy.
Strategic Synergies and Prudent Practices: The Path to Capital Efficiency in Biotech
Capital Efficiency is the lifeline that financially sustains innovation and propels growth in the intricate world of biotech startups. Any seasoned CEO has witnessed the transformative power of strategic synergies and prudent practices in steering DeepTech ventures towards impact and success.
Viva in Vitro en Foro Región de Murcia: destino inversor
Nuestra compañía ha sido elegida como uno de los proyectos más innovadores parar representar a nuestro ecosistema empresarial en el “Foro Región de Murcia, destino inversor”, organizado por El Confidencial.
Dr Rebecca Coll (Queen’s University Belfast) joins Viva’s Scientific and Advisory Board
Dr Rebecca Coll (Queen’s University Belfast) has joined Viva’s Scientific and Advisory Board, which continues to be strengthened following the addition of Dr Eduardo Lopez Collazo in January.
Viva incorporates Dr. Eduardo López Collazo into its Advisory and Scientific Committee
Dr. Eduardo López Collazo has signed an agreement with Viva In Vitro to become a member of its Advisory and Scientific Committee, thus reinforcing a project that seeks to generate an important impact in the field of inflammasome biomedicine focused on the development of solutions and services for research, pharmaceutical companies and hospitals.
Viva in Vitro is chosen by APTE as one of the TOP 100 Startups 2023
Our company has been recognised as one of the #TOP100 best startups of 2023, according to the Association of Science and Technology Parks of Spain (APTE).
Viva In Vitro: a pioneering company among the 650 startups with ENISA recognition in 2024
Viva in Vitro achieves ENISA certification as an emerging biotechnology company, leader in sepsis research.
La empresa Viva In Vitro Diagnostics, SL, ha sido reconocida con el prestigioso Premio Empresarial CEI Mare Nostrum
La empresa Viva In Vitro Diagnostics, SL, ha sido reconocida con el prestigioso Premio Empresarial CEI Mare Nostrum en la ceremonia de los II Premios
Viva in Vitro Opens New Facilities at the Murcia Science Park
The emerging biomedical company Viva in Vitro has moved from the Murcian Institute of Health Research (IMIB) to its new headquarters, inaugurated today at the Murcia Science Park.
Viva in Vitro amplía su equipo científico atrayendo talento expatriado
Viva in Vitro amplía su equipo científico atrayendo talento expatriado
La biotech Viva in Vitro alcanza los 1,2 millones de euros de inversión para prevenir la sepsis en hospitales de todo el mundo
Surgida como spinoff del Instituto Murciano de Investigación Biosanitaria (IMIB), abre así una nueva etapa en la que se ampliará el equipo científico y de gestión, y